FHS reports institutional grant support from Celgene, GlaxoSmithKline, Janssen, Oncopeptides AB, and Sanofi; payment or honoraria (personal) from Amgen, Bristol Myers Squibb, Celgene, Janssen, Novartis, Oncopeptides AB, Schain, Skylite DX, and Takeda; advisory board or safety monitoring board participation for AbbVie, Amgen, Celgene, Janssen, Novartis, and Oncopeptides AB; and stock or stock options from Nordic Nanovector, outside of the submitted work. FHS sold stock or stock options in Oncopeptides AB on Jan 4, 2022. NAB reports employment at Oncopeptides AB and stock or stock options from Oncopeptides AB, outside of the submitted work. PS reports grants or contracts from Amgen, Celgene, Janssen, SkylineDx, and Takeda, and payment or honoraria from Amgen, Celgene, Janssen, SkylineDx, and Takeda, outside of the submitted work.